Products for Research Use Only

NYX-2925

CAT: 0804-HY-135741-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-135741-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
NYX-2925 is an orally active NMDAR modulator. NYX-2925 restores levels of activated Src and Src phosphorylation sites on GluN2A and GluN2B in the mPFC. NYX-2925 shows no effect on CAMKII, and any addictive or sedative/ataxic side effects. NYX-2925 can be used for research of a variety of NMDA receptor-mediated central nervous system disorders[1][2].
CAS Number
2012536-16-0
UNSPSC
12352005
Target
IGluR
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel; Neuronal Signaling
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/nyx-2925.html
Concentration
10mM
Purity
98.77
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC(C)C(N1[C@@]2(CCC1)C(N(C2)[C@H](C(N)=O)[C@H](O)C)=O)=O
Molecular Formula
C14H23N3O4
Molecular Weight
297.35
References & Citations
[1]Morrison G, et al. The NMDAR modulator NYX-2925 alleviates neuropathic pain via a Src-dependent mechanism in the mPFC. Neurobiol Pain. 2019 Dec 4;7:100039. |[2]Khan MA, et al. NYX-2925 Is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory. Int J Neuropsychopharmacol. 2018 Mar 1;21 (3) :242-254.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
NMDA Receptor